8,700 Studies Reviewed. 87.0% Found Biological Effects. The Evidence is Clear.
Shield Your Body
Cancer & Tumors869 citations

Chou C-K, A Guy, LL Kunz, RB Johnson, JJ Crowley and J. H

Bioeffects Seen

Chou C-K, A Guy, LL Kunz, RB Johnson, JJ Crowley and J · 1992

View Original Abstract
Share:

Insufficient information to determine key finding.

Plain English Summary

Summary written for general audiences

Insufficient information to generate summary. The provided record contains only author names and publication year (1992) with no title, abstract, or other details that would indicate the study's subject matter or findings.

Why This Matters

Complete bibliographic information including title and abstract is needed to evaluate this study's relevance to EMF health effects research.

Exposure Information

Specific exposure levels were not quantified in this study.

Cite This Study
Chou C-K, A Guy, LL Kunz, RB Johnson, JJ Crowley and J (1992). Chou C-K, A Guy, LL Kunz, RB Johnson, JJ Crowley and J. H.
Show BibTeX
@article{chou_c_k_a_guy_ll_kunz_rb_johnson_jj_crowley_and_j_h_ce4874,
  author = {Chou C-K and A Guy and LL Kunz and RB Johnson and JJ Crowley and J},
  title = {Chou C-K, A Guy, LL Kunz, RB Johnson, JJ Crowley and J. H},
  year = {1992},
  doi = {10.1186/s12943-020-01234-1},
  url = {http://www.saferemr.com/2016/06/national-toxicology-program-not-first.html},
}
DOI: 10.1186/s12943-020-01234-1

Quick Questions About This Study

Regulatory T cells (Tregs) are immune cells that normally prevent autoimmune reactions but unfortunately also suppress the body's natural ability to detect and destroy cancer cells, making tumors harder to treat.
Tregs share many molecular pathways with beneficial immune cells and are essential for preventing autoimmune diseases, so eliminating them could cause serious immune system dysfunction throughout the body.
Foxp3 is the master control protein that defines regulatory T cells. It acts like a molecular switch that determines whether immune cells will suppress or activate immune responses against potential threats.
Costimulatory and inhibitory receptors on Tregs act like accelerator and brake pedals, controlling how strongly these cells suppress immune responses and representing potential targets for cancer immunotherapy development.
Researchers are developing combination therapies using checkpoint inhibitors and other approaches to selectively reduce Treg activity specifically within tumors while preserving their protective functions elsewhere in the body.